Friedreich’s ataxia (FA) is a rare neurodegenerative disease (ND). Its prevalence is usually found in those of Indo-European and Afro-Asiatic origin. Frataxin (FXN), a low-molecular-weight protein of 23kDa found in mitochondria, plays a pivotal role in the etiopathogenesis of FA. Therefore, a wide array of therapeutics has been targeted at FXN. This chapter throws light on multifarious therapeutics employed to combat FA in cell and animal models and human subjects. A few possible mechanistic roles of plant-based compounds and dietary ingredients have been discussed. It also emphasizes the pitfalls in current therapeutics that need more attention.
Tuesday, July 5, 2022
Efficacy of plant extracts against Friedreich’s ataxia
Magisetty Obulesu, Plant Extracts in Neurodegenerative Diseases, Academic Press, Chapter 4, Pages 47-60, 2022, doi:10.1016/B978-0-323-95762-5.00006-0.
